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Abstract - The endocannabinoid CB1 receptor has been implicated in the inhibitory 
control of learning and memory. In the present experiment, we compared the behavioral 
response of CB1 receptor knockout mice (CB1R-/-) with animals administered CB1 
receptor antagonist/inverse agonist SR141716A (Rimonabant; 3 mg/kg IP, 30 min pre-
trial) in terms of acquisition and retention of a habituation task and changes in cerebral 
monoamines. The results can be summarized as follows: (i.) The acute and chronic 
invalidation of the CB1 receptor resulted in an increase of behavioral habituation during 
the first exposure to an open field, indicative of enhanced acquisition of the task; (ii.) 
CB1R-/- mice, but not rimonabant-treated animals, showed enhanced long-term retention 
of the habituation task when tested 48 hours and 1 week subsequent to the first 
exposure to the open field, respectively; (iii.) The facilitation of long-term retention of the 
habituation task in CB1R-/- mice was accompanied by a selective and site-specific 
increase in serotonin activity in hippocampus; and (iv.) Rimonabant-treated animals 
displayed ‘antidepressant-like’ alterations of cerebral monoamines, that is, most 
parameters of monoaminergic activity were increased especially in dorsal striatum and 
hippocampus. Taken together, the present findings demonstrate that the genetic 
disruption of the CB1 receptor gene can cause an improvement of behavioral 
habituation, which is considered to represent a form of ‘non-associative’ learning. 
Furthermore, the data support our assumption of a rimonabant-sensitive cannabinoid 
receptive site that is different from the ‘classical’ CB1 receptor and which, under 
physiological conditions, might be involved in the inhibitory control of the acquisition but 
not retention of non-associative learning tasks. 
Keywords: Rimonabant; CB1-knockout; Hippocampus; Habituation; Biogenic amines 
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Introduction 
The endocannabinoid system is an important neuromodulatory system in the brain. 
Several neuropsychological functions are under control of the cannabinoid receptor 
subtype 1 (CB1 receptor) and of its endogenous lipid ligands anandamide and 2-
arachidonoylglycerol, respectively. CB1 receptors are present at different levels in 
several brain regions like frontal cortex, dorsal/ventral (nucleus accumbens) striatum, 
hippocampal formation, septum, and amygdala complex (Fride, 2005; Marsicano & 
Lutz, 2006). At physiological and pathophysiological level, endocannabinoids have been 
shown to play regulatory roles in several ‘integrative’ behavioral responses including 
locomotion, anxiety- and depressive-like states as well as cardiovascular, feeding and 
pain control (Pacher, Batkai & Kunos, 2006). Of special interest is the potential role of 
endocannabinoids in ‘cognitive’ functioning, that is, neural processes related to learning 
as well as memory consolidation and retention. A follow-up of behavioral experiments 
using animals with a genetic or pharmacological blockade of the CB1 receptor indicates 
that under physiological conditions endocannabinoids might exert an inhibitory control 
over mnemonic processes. Thus, reducing the endocannabinoid tone by either 
destruction of the CB1 receptor gene or by blocking endocannabinoid transmission at 
CB1-receptive sites resulted in a facilitation of learning and memory processing (for 
review see Lichtman, Varvel & Martin, 2002). 
Up to now, almost all experiments aimed at investigating the functional role of 
(endo)cannabinoids in mnemonic functions were conducted with animal models of 
‘associative’ learning and memory, that is, examining cannabinoid effects on acquisition, 
retention and extinction of tasks with explicitly defined stimulus-response contingencies 
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like the radial-arm (Lichtman, 2000) and Morris water maze (Varvel & Lichtman, 2002), 
inhibitory avoidance (Barros, Carlis, Maidana, Silva, Baisch, Ramirez & Izquierdo, 
2004), and fear conditioning (Marsicano, Wotjak, Azad, Bisogno, Rammes, Cascio, 
Hermann, Tang, Hofmann, Zieglgansberger, Di Marzo & Lutz, 2002). The role of the 
endocannabinoid tone in ‘non-associative’ learning function remains to be elucidated. 
Consequently, the aim of the present study was to examine the effects of genetic and 
pharmacological blockade of the CB1 receptor with rimonabant on behavioral 
habituation, a form of non-associative learning. In rodents, habituation can be measured 
by examining exploratory behavior in a novel environment and is reflected by a 
decrease in vertical activity (rearing) over time. With regard to the work cited above, we 
held it possible that the genetic and pharmacological blockade of the CB1 receptor could 
amplify the rate of habituation acquisition and retention. However since previous studies 
from our lab provided evidence for differential effects of a CB1 receptor knockout versus 
rimonabant treatment in various behavioral essays (Thiemann, van der Stelt, Petrosino, 
Molleman, Di Marzo & Hasenöhrl, 2007a; Thiemann, Ledent, Molleman & Hasenöhrl, 
2007b), this assumption needed to be tested. Furthermore, monoaminergic neurons are 
crucially involved in the control of behavioral processes related to exploration, anxiety, 
learning, and memory (Graeff, 2002; Rolls, 2000) and our recent studies showed that 
the genetic and pharmacological manipulation of the endocannabinoid system 
influenced cerebral monoamine concentrations and turnover rates (Thiemann et al., 
2007b). Therefore, we expected to find changes in the concentrations of dopamine 
(DA), serotonin (5-HT), and their metabolites in the brain of CB1R-/- and rimonabant-
treated mice. 
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Materials and methods 
Subjects  
The experiments were carried out in accordance with the Animals Scientific Procedures 
Act 1986 and were approved by the U.K. Home Office. CB1 receptor knockout (CB1R-/-) 
mice were used which were bred in-house from CD1 backcrossed mice (Ledent, 
Valverde, Cossu, Petitet, Aubert, Beslot, Böhme, Imperato, Pedrazzini, Roques, 
Vassart, Fratta & Parmentier, 1999). The CB1R-/- mice and their littermate controls 
(CB1R+/+) were obtained by intercrossing heterozygous (CB1R+/-) breeding pairs; they 
were 3 month old and weighed 30-35 g. Genotyping was performed by a PCR-based 
assay using DNA extracted from the tail. Subjects were drug- and test-naive, and were 
used only once. The animals were maintained on a normal 12 hr light/dark cycle (lights 
on at 7.30 am) and were tested during the light phase. They were housed 4-5 per cage 
and were handled and weighed daily for 7 days before the start of the experiments. 
 
Drugs  
Rimonabant (SR141716A; Sanofi-Synthelabo, France; Rinaldi-Carmona, Barth, 
Heaulme, Alonso, Shire, Congy, Soubrie, Breliere & Le Fur 1995) was dissolved in 
0.9% saline containing 2% ethanol. Rimonabant was administered at a dosage of 3 
mg/kg which proved effective in previous studies investigating the effects of the 
compound in terms of locomotor activity (Compton, Aceto, Lowe & Martin, 1996), 
fear/anxiety (Haller, Bakos, Szirmay, Ledent & Freund, 2002), and psychostimulant-
induced behavioral sensitization (Thiemann et al., 2007a). The animals of the control 
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group received the vehicle and all injections were IP in a volume of 5.0 ml/kg body 
weight. 
 
Apparatus and Behavioral Procedure  
Habituation was measured in square open-field compartments (40 x 40 x 50 cm; black 
floor and walls) which were set up in a sound-protected experimental chamber adjacent 
to the animal holding facility. The open-field compartments were placed on top of an 
under light that provided infrared illumination to a closed-circuit video camera mounted 
2 m above the apparatus. The digitized image of the path taken by each animal was 
stored and analyzed post hoc with a video tracking system (EthoVision; Noldus, The 
Netherlands) which determined the position of the animal in the open field 5 times per 
second. Thirty minutes before the first exposure to the open field (acquisition), wild-type 
mice were administered either rimonabant (3 mg/kg; IP) or vehicle; the CB1R-/- mice 
received vehicle only. After the first exposure, the mice were re-exposed to the open 
field after three time intervals: at 4 hours after acquisition, in order to assess short-term 
memory (STM), and at 48 hours and 1 week after the first exposure, in order to assess 
long-term memory (LTM) of the task, respectively (Izquierdo, Medina, Vianna, Izquierdo 
& Barros, 1999). Thirty min prior to the retention tests, animals were administered 
vehicle (CB1R-/- mice) or 3 mg/kg rimonabant IP (CB1R+/+ mice). Two behavioral 
parameters, rearing (i.e. standing on the hind legs with the forelegs in the air or against 
the wall) and locomotion (i.e. horizontal movements in m), were registered during each 
5-min session (see Gerhardt, Hasenöhrl, Hock & Huston, 1993, for details). To 
determine the amount of habituation during the 4 hour, 48 hour and 1-week follow-up 
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sessions, the amount of rearing behavior was expressed as percentages of the 
corresponding values of the control group. Furthermore, the sojourn time in the central 
zone (20 x 20 cm) of the open field was measured to assess possible anxioactive 
properties of the genetic manipulation and pharmacological treatment, respectively. 
 
Neurochemical analysis  
After the end of behavioral testing the animals of the different treatment groups 
underwent post-mortem neurochemical analysis. The animals were decapitated, their 
brains were quickly removed, and the medial frontal cortex (cortical tissue anterior to the 
genus of the corpus callosum), ventral striatum (nucleus accumbens, olfactory tubercle, 
anterior parts of ventral pallidum), neostriatum (anterior parts of caudate-putamen with 
globus pallidus as posterior border) and the hippocampus (anterior parts of the 
hippocampal formation with CA1, CA3 and dentate gyrus), were dissected out bilaterally 
on ice. Following dissection, the samples of brain tissue were weighed, placed in plastic 
tubes containing 0.5 ml of 0.1 M perchloric acid, and then homogenized and 
centrifuged. The resulting supernatant was filtered through 0.2 µm syringe filters 
(Chromacol, UK) and the extracts were stored at -70°C until HPLC-EC analysis. The 
tissue samples were analyzed for norepinephrine (NA), serotonin (5-HT), 5-
hydroxyindole acetic acid (5-HIAA), dopamine (DA), dihydrophenylacetic acid (DOPAC) 
and homovanillic acid (HVA) levels. The HPLC system consisted out of a Waters 1525 
Binary HPLC pump, a Waters 717 plus autosampler, a Waters 2465 Electrochemical 
Detector and a spherisorb 5 µm analytical column ODS2 (4.6 x 250 mm; Waters, U.K.) 
set at 29°C. The flow cell consisted out of a glassy carbon working electrode, 2.0 mm in 
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diameter, and an ‘in situ’ silver reference electrode. The mobile phase consisted out of 
920 ml double distilled water, 6.599 mg sodium dihydrogen phosphate (NaH2PO4; 
Sigma, U.K.), 197.2 mg Pic B8 (containing water, octane sulfonic acid, methyl alcohol 
and acetic acid; Waters, U.K.), 8 ml acetonitrile (CH3CN; Sigma, U.K.) adjusted to a pH 
of 2.9 with 0-Phosphoric acid. The mobile phase was filtered using 0.2 µm disc filters 
(Sigma-Aldrich, UK) and degassed using nitric oxygen (NO). The mobile phase flow rate 
was 0.9 ml/min and a Waters 2465 EC detector was set at 0.7 mV. To quantify the 
sample peaks each chemical (NA, DA, DOPAC, HVA, 5-HT, 5-HIAA) was compared 
with external standards (Sigma, U.K.) that were prepared freshly and injected before 
and after each sample run.  The tissue samples were analyzed for 5-HT (serotonin), 5-
hydroxyindole acetic acid (5-HIAA), dopamine, dihydrophenylacetic acid (DOPAC), and 
homovanillic acid (HVA) levels using HPLC with electrochemical detection (see 
Thiemann et al., 2007b for technical details). 
 
Statistical analysis  
For the analysis of behavioral and neurochemical data, Mann-Whitney U tests (two-
tailed) for independent measures were used. 
 
Results 
Habituation to novelty  
Figure 1 depicts the amount of locomotor activity and the number of rearing measured 
for each group during the first 5-min exposure to the open field (acquisition) expressed 
as successive 1 min intervals. The three treatment groups showed a gradual decrease 
 9 
in horizontal locomotor activity across time (Fig. 1A.), which was accompanied by a 
steady increase of vertical activity during the first 3 min of the observation period (Fig. 
1B.). However, during the last two minutes CB1R-/- mice as well as animals administered 
rimonabant showed less rearing compared with vehicle controls indicative of enhanced 
acquisition of the habituation task (0.03 < P-values < 0.05). The three groups did not 
differ from each other in the time spent in the centre of the open field (range: 40.6 ± 6.9 
to 55.4 ± 8.0 s; P-values > 0.05). The effects of the acute and chronic blockade of the 
CB1 receptor on short and long-term retention of the habituation task are shown in 
Figure 2A. The mice administered rimonabant in a dosage of 3 mg/kg did not differ from 
controls in the amount of rearing when re-exposed to the open field after each of the 
three different inter-trial intervals (corresponding P-values > 0.05). No significant change 
in vertical activity was observed in CB1R-/- mice when tested 4 hours after the first 
exposure (P > 0.05); however a marked decrease in rearing was apparent after 48 
hours (P = 0.01 vs. Controls; P = 0.04 vs. rimonabant treated mice) as well as after 1 
week following the acquisition trial (P = 0.04 vs. Controls), suggestive of a CB1 receptor 
disruption induced amplification of long-term retention performance. During the three 
different retention test trials, the groups of animals did not significantly differ from each 
other in gross locomotor activity (Fig. 2B) as well as in sojourn time in the centre of the 
open field (Fig. 2C; corresponding P-values > 0.05).  
 
Brain monoamines  
In CB1R-/- mice, a decrease in serotonin concentrations was observed in hippocampus 
(P = 0.05) which was accompanied by an increase in 5-HT (5-HIAA/5-HT) turnover (P = 
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0.046). On the other hand, in animals administered rimonabant concentrations of 
dopamine, DOPAC and 5-HIAA were enhanced in hippocampus (DA: P = 0.02; 
DOPAC: P = 0.005; 5-HIAA: P = 0.012) and dorsal striatum (DA: P = 0.003; DOPAC: P 
= 0.02; 5-HIAA: P = 0.001); serotonin concentrations were increased in the dorsal 
striatum (P = 0.005). Apparent differences between rimonabant-treated and CB1R-/- 
mice were evident with regard to frontal cortex 5-HT turnover, which was decreased in 
the latter group (P = 0.05); furthermore, CB1R-/- mice had lower concentrations of DA (P 
= 0.026), 5-HT (P = 0.046) and 5-HIAA (P = 0.038) in hippocampus and reduced levels 
of DA (P = 0.015), HVA (P = 0.016), 5-HT (P = 0.009) and 5-HIAA levels (P = 0.015) in 
dorsal striatum compared with the rimonabant treated group. 
 
Discussion 
Our data are in line with the results of a recent study showing that the deletion of the 
CB1 receptor can improve non-associative learning (Degroot, Salhoff, Davis & Nomikos, 
2005) and support the general idea that endocannabinoids are involved in the inhibitory 
control of learning and mnemonic functions. Accordingly, we found that the functional 
invalidation of the CB1 receptor gene resulted in a facilitation of both acquisition and 
long-term retention of habituation. On the other hand, the acute blockade of the CB1 
receptor with rimonabant enhanced acquisition of habituation but failed to amplify long-
term retention of the task. The differential effect of a genetic invalidation versus 
pharmacological blockade of the CB1 receptor with rimonabant on habituation is not 
surprising in the light of our previous studies demonstrating similar differences with 
regard to behavioral sensitization (Thiemann et al., 2007a) and emotional reactivity 
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(Thiemann et al., 2007b). Here, rimonabant potentiated psychostimulant-sensitization 
and increased anxiety whereas the genetic invalidation of the CB1 receptor had opposite 
effects and reduced behavioral sensitization and failed to influence fear and anxiety-
related behaviors. Thus, our data supports the assumption of a specific rimonabant-
sensitive cannabinoid receptive site that is different from the ‘classical’ CB1 receptor (Di 
Marzo, Breivogel, Tao, Bridgen, Razdan, Zimmer, Zimmer & Martin, 2000) which, under 
physiological conditions, seems to be involved in the inhibitory control of the acquisition 
but not retention of non-associative learning. 
It is significant to note that the results observed in CB1R-/- mice and rimonabant-
treated animals were not confounded by non-specific effects on general locomotor 
activity and emotional reactivity, as the two groups of mice had the same activity level 
and central sojourn time during the different habituation sessions compared to vehicle 
controls. Thus, enhanced habituation learning and retention rather than motoric 
deficiency and/or changes in the emotional state may account for the observed 
decrease in exploratory behavior. The fact that habituation was improved is of general 
importance for the evaluation of the role of the endocannabinoid tone in associative 
learning and memory processes (Barros et al., 2004; Lichtman, 2000; Marsicano et al., 
2002), since for one habituation does not involve application of conventional reinforcers, 
such as food or escape from or avoidance of aversive stimulation and secondly since 
endocannabinoids are known to play a pivotal role in stress, fear/anxiety and pain 
control (Pacher et al., 2006 for review), which are important factors in aversive 
conditioning, but not for habituation. This makes an interpretation of the performance 
enhancement following CB1 receptor invalidation by genetic or pharmacological means 
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simply in terms of an interaction between the genetic/pharmacological manipulation and 
physiological processes induced by a punishing/aversive stimulus, unlikely. 
Brain monoaminergic systems are known to play important roles in processes 
underlying learning and memory. In our CB1R-/- mice, the concentration of serotonin was 
decreased in the hippocampus while 5-HIAA/5-HT turnover rates were increased in this 
brain region suggestive of an enhanced indolamine tone. It is accepted that exploration 
of an unfamiliar environment (Vanderwolf’s (1969) Type I, ‘theta’ behavior, including 
walking, sniffing, and rearing) is associated with increased dentate field excitatory 
postsynaptic potentials (fEPSPs) to perforant path stimulation (Weiler, Hasenöhrl, van 
Landeghem, van Landeghem, Brankack, Huston & Haas, 1998). Furthermore, it was 
found recently that exposure to a novel environment is paralleled by increased 
hippocampal 5-HT turnover (Storey, Robertson, Beattie, Reid, Mitchell & Balfour, 2006). 
Based on the results of only these few studies, detailed considerations regarding the 
relationship between CB1 receptor function, monoamines, and behavioral habituation 
would be premature. However, because CB1 receptor gene disruption led to enhanced 
habituation learning/retention and increased serotonin turnover in the hippocampus, one 
could speculate that the behavioral effects of the CB1 receptor gene disruption might be 
partly related to changes in monoaminergic correlates involved in the process of 
suppressing the biological significance of and attention to a repeatedly presented 
stimulus configurations. Rimonabant is known to augment the synaptic concentration of 
biogenic amines similarly to antidepressant drugs, that is, it enhances the synaptic 
availability of serotonin and, to a lesser extent, dopamine in the brain (Witkin, Tzavara & 
Nomikos, 2005). Our post-mortem neurochemistry results are in line with the proposed 
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‘antidepressant-like’ neurochemical profile of the compound. The injection of rimonabant 
resulted in a marked increase in monoamine concentrations in the hippocampus and 
dorsal striatum, respectively, which might be instrumental to the observed facilitation of 
the acquisition of the habituation task (Thiel, Müller, Huston & Schwarting, 1999). 
Furthermore, a clear distinction in the neurochemical profile between CB1R-/- mice and 
rimonabant-treated animals was apparent providing additional neurochemical evidence 
for the existence of a rimonabant-sensitive receptive site in the brain, which is different 
to the classical CB1 receptor. 
What are the functional implications of the present results in terms of learning 
and memory retention? Our findings provide supportive evidence for the hypothesis that 
the endocannabinoid system is involved in the inhibitory control of associative 
processing in a way similar to endogenous opiates (Izquierdo, 1982) and neuronal 
histamine (Huston, Wagner & Hasenöhrl, 1997). CB1R-/- mice displayed enhanced 
acquisition and prolonged retention of the habituation task compared to wild-type 
controls and this inability to forget may result in behavioral perseveration evidenced in 
more complex learning paradigms like the Morris water maze (Varvel & Lichtman, 
2002). Thus, it is feasible that cannabinoids disrupt memory through a CB1 receptor 
mechanism of action, and that under physiological conditions the endocannabinoid 
system may have a paramount role in facilitating extinction and/or forgetting processes 
(Marsicano et al., 2002). 
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FIGURE LEGENDS 
 
Figure 1. Temporal effect of genetic and pharmacological disruption of the CB1 receptor 
on A. the mean (+SEM) distance moved and B. the mean (±SEM) number of rearing 
during the first exposure to the open field (acquisition trial). CB1R+/+ mice were 
administered rimonabant (3 mg/kg) or vehicle (controls; 0.5 ml/kg; IP) 30 min pre-trial. 
CB1R-/- animals received vehicle only. The 5-min test period is depicted as successive 
1-min intervals. Sample size was 8 per group. Measure of effect: *P < 0.05, indicative of 
superior acquisition of the habituation task. 
 
Figure 2. Effect of genetic and pharmacological disruption of CB1 receptor on A. the 
number of rearing expressed as mean (-SEM) percentage of CB1+/+ controls, B. mean 
(+SEM) horizontal locomotor activity, and C. mean (+SEM) sojourn time in the centre of 
the open field. Measurements were taken 4 hours, 48 hours, and 1 week after the first 
exposure to the open field, respectively. Raw data of rearing for controls was: 4 hours = 
29.87 ± 3.54; 48 hours = 41.52 ± 4.05; 1 week = 39.49 ± 3.54. Sample size was 8 per 
group. Measure of effect based on statistical analysis of raw data: *P < 0.05 vs. controls 
and #P < 0.05 vs. rimonabant-treated animals, indicative of superior long-term retention 
of the habituation task. 
Figure 1
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Figure 2
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Table 1. Means and SEMs for the ex vivo measurements (in nanograms per milligram) and turnover quotients obtained 
upon animals sacrificed after the last 5-min test trial in the habituation task 
 
Note: Measure of effect; **P ≤ 0.01, *P ≤ 0.05 vs. CB1R+/+ Controls; ##P < 0.01, #P < 0.05 vs. Rimonabant-treated animals; 
number of animals per group = 6 to 8; n.d., not determined. 
Treatment/ 
brain region 
DA DOPAC HVA 5-HT 5-HIAA DOPAC/ 
DA 
HVA/ 
DA 
5-HIAA/ 
5-HT 
Frontal cortex 
Controls 
Rimonabant 3 mg/kg 
CB1R-/- 
 
1.01±0.50 
1.31±0.64 
2.57±1.93 
 
0.41±0.17 
0.42±0.08 
0.57±0.31 
 
n.d. 
n.d. 
n.d. 
 
1.29±0.25 
1.79±0.47 
1.67±0.35 
 
0.56±0.11 
0.73±0.19 
0.63±0.12 
 
0.50±0.06 
0.73±0.19 
0.42±0.07 
 
n.d. 
n.d. 
n.d. 
 
0.33±0.06 
0.41±0.02 
0.34±0.01# 
Hippocampus 
Controls 
Rimonabant 3 mg/kg 
CB1R-/- 
 
0.25±0.06 
0.60±0.11* 
0.26±0.07# 
 
0.12±0.03 
0.65±0.38** 
0.28±0.10 
 
n.d. 
n.d. 
n.d. 
 
1.01±0.17 
2.10±0.63 
0.68±0.14*# 
 
1.38±0.16 
3.31±0.91* 
1.39±0.24# 
 
0.44±0.08 
1.51±1.06 
0.54±0.09 
 
n.d. 
n.d. 
n.d. 
 
1.35±0.10 
1.19±0.31 
2.01±0.11* 
Dorsal striatum 
Controls 
Rimonabant 3 mg/kg 
CB1R-/- 
 
16.81±1.36 
47.81±6.39** 
19.07±1.25# 
 
3.46±0.56 
10.49±2.27* 
3.48±0.22 
 
2.00±0.42 
6.05±1.27* 
2.42±0.12# 
 
0.75±0.09 
2.05±0.26** 
0.89±0.12## 
 
0.42±0.06 
1.12±0.17** 
0.55±0.11# 
 
0.20±0.03 
0.21±0.04 
0.18±0.01 
 
0.12±0.02 
0.10±0.03 
0.14±0.01 
 
0.55±0.03 
0.55±0.04 
0.60±0.04 
Ventral striatum 
Controls 
Rimonabant 3 mg/kg 
CB1R-/- 
 
21.81±1.79 
20.93±2.12 
18.90±4.44 
 
3.93±0.35 
3.90±0.43 
4.06±0.90 
 
0.95±0.12 
0.90±0.11 
1.12±0.13 
 
1.47±0.33 
1.23±0.29 
1.45±0.11 
 
n.d. 
n.d. 
n.d. 
 
0.18±0.01 
0.19±0.01 
0.27±0.06 
 
0.43±0.03 
0.42±0.01 
0.52±0.01 
 
n.d. 
n.d. 
n.d. 
Table 1
